Clostridium butyricum is a spore-forming, anaerobic bacterium that lives naturally in the human gut and produces butyrate, a short-chain fatty acid that fuels the cells lining your intestines. It has been used as a probiotic in Japan and parts of Asia for decades, and a growing body of research links it to benefits ranging from preventing antibiotic-related diarrhea to improving responses to cancer immunotherapy. Despite the ominous sound of “Clostridium,” a genus that includes some dangerous species, the strains used as probiotics have a well-documented safety record and lack the toxin genes that make their relatives harmful.
A Butyrate Factory in Your Gut
Your colon depends on short-chain fatty acids for energy, and butyrate is the most important of them. While many gut bacteria produce some butyrate, C. butyricum is unusually efficient at it. The bacterium ferments dietary fiber and other carbohydrates under anaerobic conditions, churning out butyrate as a primary metabolic byproduct. That butyrate feeds colonocytes (the cells of your colon lining), helps maintain the mucus layer, and acts as a signaling molecule that dials down inflammation locally and, as emerging research suggests, even at distant sites in the body.1PubMed Central. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease
One reason C. butyricum makes a practical probiotic is its ability to form spores. Spores are dormant, tough-shelled versions of the bacterium that survive stomach acid, heat, and even many antibiotics. Once the spores reach the oxygen-free environment of the colon, they germinate and begin producing butyrate. This spore-forming ability gives C. butyricum an edge over many other probiotic species that struggle to survive the trip through the upper digestive tract.
Strengthening the Intestinal Barrier
A healthy gut lining acts like a selective gate: it absorbs nutrients while keeping bacteria and toxins on the intestinal side. When that barrier breaks down, a condition sometimes called “leaky gut,” inflammatory molecules and bacterial fragments slip through into the bloodstream and trigger immune reactions. C. butyricum appears to counteract this process by boosting the proteins that hold intestinal cells tightly together. In mouse models of colitis, the bacterium increased levels of key tight-junction proteins such as claudin-1, occludin, and ZO-1, while reducing intestinal permeability and lowering inflammatory markers like TNF-α and IL-1β.2PubMed Central. Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis A separate study confirmed these findings, showing that C. butyricum not only repaired the physical structure of tight junctions in colitis-damaged tissue but also shifted the microbial community toward a healthier profile.3PubMed. Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis
This barrier-strengthening effect is not just an academic curiosity. It is the mechanism that seems to underpin many of C. butyricum’s downstream benefits, from reducing diarrhea to calming inflammation in the colon. When the intestinal wall stays intact, fewer bacterial toxins escape, and the immune system has less reason to mount a chronic inflammatory response.
Preventing Antibiotic-Associated Diarrhea
Antibiotics save lives, but they also carpet-bomb gut bacteria, often triggering diarrhea as a side effect. This is one of the best-studied applications of C. butyricum, particularly in pediatric settings. In a study of children receiving antibiotics, diarrhea occurred in about 59% of those given antibiotics alone. Among children who also received C. butyricum MIYAIRI (CBM 588) from the start of their antibiotic course, the rate plummeted to roughly 9%. The probiotic also preserved Bifidobacterium levels, a genus of beneficial bacteria that antibiotics tend to wipe out.4PubMed. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI
The ability of C. butyricum spores to tolerate antibiotics is central to this benefit. Because the spores are resistant to many common antibiotics, you can take them alongside your prescription without the drug destroying the probiotic before it has a chance to work. Research in juvenile mice confirmed that C. butyricum reduces intestinal inflammation and restores barrier function even under continuous antibiotic exposure, and that its therapeutic effects are tightly linked to this antibiotic tolerance.5PubMed Central. Clostridium butyricum RH2 ameliorates diarrhea in juvenile mice under continuous antibiotic exposure by modulating gut microbiota and metabolome The mechanism goes beyond simply surviving antibiotics: CBM 588 also increases populations of Bifidobacterium, Lactobacillus, and Lactococcus species in the disrupted microbiome, helping the gut ecosystem recover faster.6iScience. Clostridium butyricum MIYAIRI 588 Upregulates IL-17A-Producing γδT Cells and Anti-inflammatory Metabolites to Protect against Antibiotic-Induced Dysbiosis
Inflammatory Bowel Disease
Ulcerative colitis and Crohn’s disease involve chronic, damaging inflammation of the intestinal tract. While no probiotic replaces standard medications for these conditions, C. butyricum has shown promising anti-inflammatory effects in animal models and early-stage research. In a rat model of colitis, treatment with C. butyricum lowered serum levels of key pro-inflammatory molecules with efficiency comparable to, and in some measures better than, mesalamine, a standard drug for ulcerative colitis.7PubMed Central. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats
One mechanism behind this effect involves the immune system. C. butyricum stimulates a certain signaling pathway in immune cells within the inflamed gut lining, prompting them to produce interleukin-10, an anti-inflammatory molecule. In effect, the bacterium appears to coax the immune system toward a calmer state rather than suppressing it outright.8PubMed. A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease More recent work has explored whether tiny particles shed by C. butyricum, called extracellular vesicles, might carry some of these anti-inflammatory signals. In colitis mice, these vesicles suppressed pro-inflammatory pathways, reduced the abundance of harmful bacteria like E. coli and Shigella, and improved intestinal barrier integrity through effects on tryptophan metabolites.9PubMed. Anti-Inflammatory Effect of Clostridium butyricum-Derived Extracellular Vesicles in Ulcerative Colitis: Impact on Host microRNAs Expressions and Gut Microbiome Profiles
The pairing of C. butyricum with a prebiotic fiber can amplify these effects. When researchers combined C. butyricum with chitooligosaccharides (a fiber derived from shellfish shells) in a mouse colitis model, the synbiotic combination outperformed either component alone, producing the greatest reductions in disease severity, mortality, and tissue damage.10PubMed Central. Clostridium butyricum and Chitooligosaccharides in Synbiotic Combination Ameliorate Symptoms in a DSS-Induced Ulcerative Colitis Mouse Model by Modulating Gut Microbiota and Enhancing Intestinal Barrier Function
Irritable Bowel Syndrome
Unlike inflammatory bowel disease, irritable bowel syndrome (IBS) does not cause visible damage to the gut, but the symptoms, including cramping, bloating, and unpredictable bowel habits, can be debilitating. C. butyricum has been tested specifically in diarrhea-predominant IBS (IBS-D), where the evidence is more encouraging. A randomized, double-blind, placebo-controlled trial found that patients taking C. butyricum had a significantly greater improvement in overall symptom scores compared to placebo after four weeks. The response rate was about 45% in the probiotic group versus roughly 31% in the placebo group, and the benefit was most pronounced in patients with moderate to severe symptoms, where the responder rate climbed above 54%.11Scientific Reports. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial
A real-world study of CBM 588 in IBS-D patients following a low-fiber diet echoed these findings, reporting more than 80% reduction in diarrhea episodes and roughly 60% improvements in stool frequency and abdominal pain.12PubMed Central.